Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$34.26

-2.46 (-6.70%)

, UNH

UnitedHealth

$160.72

2.4 (1.52%)

12:43
12/01/16
12/01
12:43
12/01/16
12:43

UnitedHealth policy for Exondys 51 a positive for Sarepta, says Credit Suisse

Credit Suisse analyst Alethia Young noted that Sarepta (SRPT) shares have been weak since UnitedHealth (UNH) posted its medical benefit policy for the company's DMD drug Exondys 51, but she doesn't see a reason for the weakness. She doesn't think encouraging home infusions limits access and believes the requirement for an every 6 month reauthorization is neither "prohibitive nor concerning" as it is standard with expensive rare disease treatments. She sees the policy as a positive for Sarepta, as having more payers supporting Exondys reimbursement makes it hard for other payers not to do so, and keeps an Outperform rating on Sarepta shares.

SRPT

Sarepta

$34.26

-2.46 (-6.70%)

UNH

UnitedHealth

$160.72

2.4 (1.52%)

SRPT Sarepta
$34.26

-2.46 (-6.70%)

10/27/16
WEDB
10/27/16
NO CHANGE
Target $72
WEDB
Outperform
Sarepta selloff overdone, says Wedbush
Wedbush analyst Heather Behanna said the selloff in Sarepta is overdone and recommends shares ahead of the Exondys 51 launch update in January. The analyst has an Outperform rating and a $72 price target on Sarepta shares.
11/11/16
LEER
11/11/16
NO CHANGE
Target $55
LEER
Market Perform
Sarepta Exondys 51 launch expectations seem too high for 2017, says Leerink
Leerink analyst Joseph Schwartz believes Sarepta Exondys 51 launch expectations may be too high for 2017. While nothing that a true Duchenne muscular dystrophy prevalence remains unknown, the analyst says that a "start form" number of about 200 patients would need to be provided in early January in order for investors to be confident in 2017 consensus sales estimates of $215M. Additionally, Schwartz points out that based on the price of Exondys 51 per vial, it currently appears that management has underestimated the true price of the drug which they will realize.
11/29/16
BARD
11/29/16
NO CHANGE
Target $102
BARD
Outperform
Baird sees strong launch for Sarepta after surveying neurologists
After his firm surveyed 30 neurologists treating at least ten Duchenne muscular dystrophy patients and at least five suspected/confirmed patients amenable to exon-51 skipping, Baird analyst Brian Skorney believes Sarepta Therapeutics' Exondys 51 is positioned for a strong launch. In a research note earlier today, Skorney said that most of the 30 doctors surveyed seem convinced of the drug's efficacy, and plan to start prescribing the drug in the next year. The drug's consensus sales estimate for its first quarter on the market of $7.1M may be understating sales, Skorney wrote. The analyst continues to expect $11M of Exondys 51 sales in Q4. He has an Outperform rating on shares of Sarepta with a $102 price target. The stock is up 34c, or 1%, to $36.62 in morning trading.
12/01/16
RBCM
12/01/16
NO CHANGE
RBCM
Outperform
Sarepta DMD drug still likely to be covered by UnitedHealth, says RBC Capital
RBC Capital analyst Simos Simeonidis said some language in UnitedHealthcare's (UNH) Commercial Drug Policy for Sarepta's (SRPT) Exondys 51 may have "spooked" investors, but he continues to believe that the DMD drug will end up being covered by the insurer. The analyst, who would be a buyer of Sarepta amid this weakness, keeps an Outperform rating on the stock.
UNH UnitedHealth
$160.72

2.4 (1.52%)

11/30/16
UBSW
11/30/16
NO CHANGE
Target $193
UBSW
Buy
UnitedHealth price target raised to $193 from $180 at UBS
UBS analyst A.J. Rice raised his price target on UnitedHealth to $193 from $180 following its very positive investor day. The company said they see strong growth driven by both group and individual markets while controlling their commercial medical cost trend, noted Rice, who reiterated his Buy rating on UnitedHealth shares.
11/30/16
COWN
11/30/16
NO CHANGE
Target $175
COWN
Outperform
UnitedHealth price target raised to $175 from $150 at Cowen
Cowen analyst Christine Arnold raised her price target on UnitedHealth to $175 from $150 reflecting the company's guidance provided at its analyst day.The analyst said UnitedHealth remains a top pick for 2017 as it has an abundance of tailwinds and minimal company-specific headwinds. Arnold reiterated her Outperform rating on UnitedHealth shares.
11/30/16
SBSH
11/30/16
NO CHANGE
Target $178
SBSH
Buy
UnitedHealth price target raised to $178 after analyst day at Citi
Citi analyst Ralph Giacobbe said UnitedHealth's "upbeat tone" at its investor day matched the company's "impressive" 2017 guidance, saying the company remains in an enviable position of having size, scale, and infrastructure to invest while expanding its reach via Optum. Giacobbe raised his price target on UnitedHealth shares to $178 from $164 and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$10.80

0.25 (2.37%)

16:01
12/04/16
12/04
16:01
12/04/16
16:01
Hot Stocks
Aduro Biotech reports presentation of BION-1301 data »

Aduro Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

15:59
12/04/16
12/04
15:59
12/04/16
15:59
Hot Stocks
Trillium Therapeutics reports presentation of TTI-621 data »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLUE

bluebird bio

$69.75

1.1 (1.60%)

15:47
12/04/16
12/04
15:47
12/04/16
15:47
Hot Stocks
bluebird bio reports new data from HGB-205 study of LentiGlobin »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

15:43
12/04/16
12/04
15:43
12/04/16
15:43
Hot Stocks
Bellicum Pharmaceuticals reports updated data from BPX-501 study »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

15:39
12/04/16
12/04
15:39
12/04/16
15:39
Hot Stocks
Alnylam reports Phase 1 givosiran data, says plans Phase 3 study late 2017 »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$31.63

0.17 (0.54%)

, ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

15:32
12/04/16
12/04
15:32
12/04/16
15:32
Hot Stocks
Spark Therapeutics, Pfizer report updated preliminary data on SPK-9001 »

Spark Therapeutics (ONCE)…

PFE

Pfizer

$31.63

0.17 (0.54%)

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

15:26
12/04/16
12/04
15:26
12/04/16
15:26
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$27.20

-0.1 (-0.37%)

15:21
12/04/16
12/04
15:21
12/04/16
15:21
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.